v3.26.3
Summary of Significant Accounting Policies - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Research and development $ 19,491 $ 11,948 $ 54,943 $ 31,126
Net loss (25,825) (18,040) (76,352) (51,475)
Reportable Segment        
Segment Reporting [Line Items]        
Share-based compensation 5,316 2,379 14,781 9,755
Other segment items (2,928) (1,467) (7,188) (5,326)
Net loss 25,825 18,040 76,352 51,475
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense | Reportable Segment        
Segment Reporting [Line Items]        
Wages and benefits 2,257 2,450 6,936 7,832
Other general and administrative expenses 2,921 3,299 9,694 9,550
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Reportable Segment        
Segment Reporting [Line Items]        
Wages and benefits 3,558 1,940 9,383 5,200
Unallocated research and development expenses 596 521 1,636 1,454
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Reportable Segment | Tibulizumab SSc program        
Segment Reporting [Line Items]        
Research and development 2,741 3,054 10,149 7,251
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Reportable Segment | Tibulizumab HS program        
Segment Reporting [Line Items]        
Research and development 3,913 2,657 13,302 5,931
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Reportable Segment | Tibulizumab PMR program        
Segment Reporting [Line Items]        
Research and development 2,161 0 2,665 0
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Reportable Segment | Tibulizumab program general        
Segment Reporting [Line Items]        
Research and development 5,025 2,726 14,379 8,597
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Reportable Segment | Additional product candidates (torudokimab and crebankitug)        
Segment Reporting [Line Items]        
Research and development $ 265 $ 481 $ 615 $ 1,231